ASCO GU 2022

Neoadjuvant therapy in UTUC: Good options for selected…

Role of PARPi in urothelial cancer

Exciting data supports trimodality therapy

ADC shape the therapy landscape in urothelial cancer

ADCs will be step-changing in urothelial cancers

Mature data confirm efficacy of maintenance avelumab as…

Follow-up data confirm OS benefit across subgroups

Patient selection for adjuvant Nivolumab (TPS vs. CPS)

Not practice changing, but hypothesis generating.

Ongoing immunotherapy innovation for mCRPC

IO escalation results in improved response in met. TCC.

Patient selection for bladder preservation

HER2 ERBB2 – entering precision oncology

Do we need testing? Which biomarkers are of relevance?

Triplet vs. doublet: Which patients should we consider?

Enza beyond progression? Practice changing or not?

The future of genetic testing. Somatic vs. germline?…

Is the dual hormone-backbone the future?

PROpel & Magnitude: who wins the race?

Subgroup analyses confirm the importance of oral daily…

PSA response correlates with OS and benefits in QoL

Should we use arbiraterone and olaparib as 1st line…

Where do PROpel and Magnitude agree?

Triplet-therapy as a novel treatment option

The need for biomarker panels in biopsy decision making

PSMA and FDG PET as biomarkers for response to LuPSMA

HRR testing: MAGNITUDE vs. PROpel

Is docetaxel still needed for hormone sensitive mCRPC?

PRESIDE indicates benefit of continuation ENZA + ADT

Exciting new compound for mCRPC

The importance of conducting HCRA

Should we use arbiraterone and niraparib as 1st line…

DARO in triplet therapy for CRPC

New therapies and molecular targets in prostate cancer

Addition of darolutamide improves OS in met.…

How to improve PSMA based radioligand therapy

Treatment options following adjuvant PD1 Therapy:…

Neoadjuvant IO+TKI Treatment: We need more data on…

Adjuvant PD1 Therapy confirms significant benefit for…

Neoadjuvant avelumab/axitinib - NeoAvAx

Frontline treatment of metastatic kidney cancer

Update in neoadjuvant therapy for kidney cancer

CheckMate final OS Follow Up and health related QoL

Data gap in 2nd line RCC: what’s new?

Update in adjuvant therapy for kidney cancer

Adjuvant Pembroluzimab update in kidney cancer

Nivo montoherapy followed by Nivi-Ipi resuce

Microbioma modification and checkpoint inhibition